\BOOKMARK [1][-]{section*.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section*.2}{Results}{}% 2
\BOOKMARK [2][-]{subsection*.3}{Identification of the in vivo WASH complex proteome}{section*.2}% 3
\BOOKMARK [2][-]{subsection*.4}{The SWIPP1019R mutation destabilizes the WASH complex}{section*.2}% 4
\BOOKMARK [2][-]{subsection*.5}{Spatial proteomics analysis of SWIPP1019R mutant mouse brain}{section*.2}% 5
\BOOKMARK [2][-]{subsection*.6}{SWIP mutant neurons display endo-lysosomal structural abnormalities}{section*.2}% 6
\BOOKMARK [2][-]{subsection*.7}{SWIPP1019R mutant brains exhibit lipofuscin accumulation and markers of cell death}{section*.2}% 7
\BOOKMARK [2][-]{subsection*.8}{SWIPP1019R mutant mice display persistent deficits in cued fear memory recall}{section*.2}% 8
\BOOKMARK [2][-]{subsection*.9}{SWIPP1019R mutant mice exhibit surprising motor deficits that are confirmed in human patients}{section*.2}% 9
\BOOKMARK [1][-]{section*.10}{Discussion}{}% 10
\BOOKMARK [1][-]{section*.11}{Acknowledgements}{}% 11
\BOOKMARK [1][-]{section*.12}{Author Contributions}{}% 12
\BOOKMARK [1][-]{section*.13}{Competing Interests}{}% 13
\BOOKMARK [1][-]{section*.14}{Resource Availability}{}% 14
\BOOKMARK [2][-]{subsection*.15}{Lead Contact}{section*.14}% 15
\BOOKMARK [2][-]{subsection*.16}{Materials Availability}{section*.14}% 16
\BOOKMARK [2][-]{subsection*.17}{Data and Code Availability}{section*.14}% 17
\BOOKMARK [1][-]{section*.18}{Materials and Methods}{}% 18
\BOOKMARK [2][-]{subsection*.19}{Animals}{section*.18}% 19
\BOOKMARK [2][-]{subsection*.20}{Human Subjects}{section*.18}% 20
\BOOKMARK [2][-]{subsection*.21}{Cell Lines}{section*.18}% 21
\BOOKMARK [2][-]{subsection*.22}{Primary Neuronal Culture}{section*.18}% 22
\BOOKMARK [2][-]{subsection*.23}{Plasmid DNA Constructs}{section*.18}% 23
\BOOKMARK [2][-]{subsection*.24}{AAV Viral Preparation}{section*.18}% 24
\BOOKMARK [2][-]{subsection*.25}{Immunocytochemistry}{section*.18}% 25
\BOOKMARK [3][-]{subsubsection*.26}{Primary antibodies}{subsection*.25}% 26
\BOOKMARK [3][-]{subsubsection*.27}{Secondary antibodies}{subsection*.25}% 27
\BOOKMARK [2][-]{subsection*.28}{Immunohistochemistry}{section*.18}% 28
\BOOKMARK [3][-]{subsubsection*.29}{Primary antibodies}{subsection*.28}% 29
\BOOKMARK [3][-]{subsubsection*.30}{Secondary antibodies}{subsection*.28}% 30
\BOOKMARK [2][-]{subsection*.31}{Western Blotting}{section*.18}% 31
\BOOKMARK [3][-]{subsubsection*.32}{Primary antibodies}{subsection*.31}% 32
\BOOKMARK [3][-]{subsubsection*.33}{Secondary antibodies}{subsection*.31}% 33
\BOOKMARK [2][-]{subsection*.34}{Immunoprecipitation}{section*.18}% 34
\BOOKMARK [2][-]{subsection*.35}{Electron Microscopy}{section*.18}% 35
\BOOKMARK [2][-]{subsection*.36}{iBioID Sample Preparation}{section*.18}% 36
\BOOKMARK [2][-]{subsection*.37}{LC-MS/MS for iBioID}{section*.18}% 37
\BOOKMARK [2][-]{subsection*.38}{LOPIT-DC Subcellular Fractionation}{section*.18}% 38
\BOOKMARK [2][-]{subsection*.39}{16-plex TMT LC-MS/MS}{section*.18}% 39
\BOOKMARK [2][-]{subsection*.40}{Mouse Behavioral Assays}{section*.18}% 40
\BOOKMARK [3][-]{subsubsection*.41}{Y-maze}{subsection*.40}% 41
\BOOKMARK [3][-]{subsubsection*.42}{Novel Object Recognition}{subsection*.40}% 42
\BOOKMARK [3][-]{subsubsection*.43}{TreadScan}{subsection*.40}% 43
\BOOKMARK [3][-]{subsubsection*.44}{Fear Conditioning}{subsection*.40}% 44
\BOOKMARK [3][-]{subsubsection*.45}{Hearing Test}{subsection*.40}% 45
\BOOKMARK [3][-]{subsubsection*.46}{Somatosensation}{subsection*.40}% 46
\BOOKMARK [1][-]{section*.47}{Quantification and statisical analysis}{}% 47
\BOOKMARK [2][-]{subsection*.48}{Imaris 3D reconstruction}{section*.47}% 48
\BOOKMARK [2][-]{subsection*.49}{Cleaved Caspase-3 Image Analysis}{section*.47}% 49
\BOOKMARK [2][-]{subsection*.50}{iBioID Quantitative Analysis}{section*.47}% 50
\BOOKMARK [2][-]{subsection*.51}{TMT Proteomics Quantitative Analysis}{section*.47}% 51
\BOOKMARK [2][-]{subsection*.52}{Module Gene Set Enrichment Analysis}{section*.47}% 52
\BOOKMARK [2][-]{subsection*.53}{Network Visualization}{section*.47}% 53
\BOOKMARK [1][-]{section*.54}{References}{}% 54
\BOOKMARK [1][-]{section*.55}{Funding Sources}{}% 55
